SynthesisInternal and emergency medicine2015
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature.
Synthesis in Internal and emergency medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism.The Cochrane database of systematic reviews · 2023Pooled it
- American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.Blood advances · 2020Guideline
- Emulation of randomized trials of direct oral anticoagulants with claims data and implications for new Factor XI inhibitors.Pharmacoepidemiology and drug safety · 2024Article
- Prognosis and risk factors in older patients with lung cancer and pulmonary embolism: a propensity score matching analysis.Scientific reports · 2020Article
- Vitamin K antagonists in the era of direct oral anticoagulants: is there still a room for their use?Internal and emergency medicine · 2017Article
- Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.Internal and emergency medicine · 2017Article
- Claims-based or clinical models for predicting 90-day post-pulmonary embolism outcomes.Internal and emergency medicine · 2017Article
- Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies.Drug safety · 2016Review
- The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal.Internal and emergency medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited information exists on the safety and efficacy of non-vitamin K oral anticoagulants (NOACs) in patients with pulmonary embolism (PE). The aim of this study is to evaluate the difference in the safety and efficacy of the NOACs in comparison to the standard treatment in patients presenting with deep vein thrombosis (DVT) and with PE using data from randomized controlled trials. MEDLINE and EMBASE databases were searched. Differences in the efficacy (recurrent VTE or death-related VTE) and in the safety (major bleeding) outcome were expressed as risk ratio (RR) with 95% confidence intervals (95% CI). Heterogeneity among the studies was assessed. Six studies (27,023 patients) were included. NOACs appeared to have a similar efficacy and safety compared to VKAs in patients presenting with PE and with DVT with a non-significant heterogeneity between the groups (efficacy: RR 0.90, 95% CI 0.72, 1.13 in PE patients and 0.93, 95% CI 0.75, 1.16 in DVT patients; χ2 0.04, p = 0.84; safety: RR 0.49, 95% CI 0.26, 0.95 in PE patients and 0.74 95% CI 0.51, 1.06 in DVT; χ2 1.10, p = 0.29). Our results suggest that the efficacy and safety of the NOACs compared to VKAs is similar between patients with PE and DVT.
Indexed as
Identifiers
25982918What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.